Yes. I would like to enter both in NPI 2010.
Both ( STXS and DNDN ) have been discussed at length on this board and represent paradigm shifts in their respective technologies. Moreover, they have extensive IP portfolios that should protect their monopolies for the immediate future.
Should the FDA approve Provenge, which I believe is highly probable, it should be at least a double from these price levels. STXS is more iffy, but I believe their approach to treating Atrial Fib.(Niobe System) is at the incubation stage of the adoption curve; both patient and physician safety are superb. I view STXS as the next ISRG and I still hold the latter tightly.
Ed